| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
EGFR-Tyrosinkinaseinhibition als prä- oder postoperativer Ansatz - EGFR tyrosine kinase inhibition: pre- or postoperatively
|
Thomas, M.
|
|
2005
|
11 |
01 |
p. 21-22
|
article
|
| 2 |
Einsatz von Erlotinib: prognostische und prädiktive Faktoren beim nichtkleinzelligen Lungenkarzinom - Application of erlotinib: prognostic and predictive factors for non-small cell lung cancer (NSCLC)
|
Eberhardt, W.
|
|
2005
|
11 |
01 |
p. 36-39
|
article
|
| 3 |
Erlotinib in der Second-Line-Therapie nichtkleinzelliger Lungenkarzinome - Erlotinib as second-line therapy for non-small cell lung cancer
|
Wolf, M.
|
|
2005
|
11 |
01 |
p. 29-35
|
article
|
| 4 |
Etablierung und Führung einer Gewebebank - Establishment and management of a tumor tissue bank
|
Allgayer, H.
|
|
2005
|
11 |
01 |
p. 7-11
|
article
|
| 5 |
Lungentumoren - Lung Tumours
|
Müller, K.-M.
|
|
2005
|
11 |
01 |
p. 12-15
|
article
|
| 6 |
Nebenwirkungen bei der Therapie des NSCLC — aus der Sicht des Pneumologen - Pneumotoxicity in therapy of NSCLC — from the point of view of a pneumologist
|
Huber, R. M.
|
|
2005
|
11 |
01 |
p. 40-44
|
article
|
| 7 |
Rash als Surrogatparameter und Management der kutanen Toxizität - Rash as a surrogate parameter and management of cutaneous toxicity
|
Reck, M.
|
|
2005
|
11 |
01 |
p. 45-48
|
article
|
| 8 |
Therapie des nichtkleinzelligen Lungenkarzinoms: Standards und Grenzen - Treatment for non-small cell lung cancer: standards and limitations
|
Manegold, C.
|
|
2005
|
11 |
01 |
p. 3-6
|
article
|
| 9 |
Tyrosinkinaseinhibition - Tyrosine kinase inhibition. From preclinical data to first-line therapy
|
Gatzemeier, U.
|
|
2005
|
11 |
01 |
p. 23-28
|
article
|
| 10 |
Tyrosinkinaseinhibitoren und monoklonale Antikörper - Tyrosine kinase inhibitors and monoclonal antibodies: preclinical and clinical results
|
Petersen, C.
|
|
2005
|
11 |
01 |
p. 16-20
|
article
|
| 11 |
Zukünftige klinische Entwicklung von Bevacizumab und Erlotinib - Future clinical development of bevacizumab and erlotinib
|
Manegold, C.
|
|
2005
|
11 |
01 |
p. 49-52
|
article
|
Journal description